```html

Kawasaki Disease – IVIG Resistance: A Comprehensive Medical Guide

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis of medium‑sized arteries that primarily affects children under 5 years of age. The mainstay of treatment is a single high‑dose infusion of intravenous immunoglobulin (IVIG) combined with aspirin. While IVIG resolves fever and inflammation in >80 % of patients, <20 % experience IVIG resistance – defined as persistent or recrudescent fever ≥36 hours after the end of the initial infusion.

IVIG resistance is clinically important because it markedly increases the risk of coronary artery abnormalities (CAAs), the most serious complication of KD.

• Incidence of KD: ~19 per 100,000 children < 5 y in the United States; highest rates in East Asian countries (up to 300 per 100,000).
• IVIG resistance rate: 10–25 % worldwide, with higher rates reported in infants <1 y and in patients with certain laboratory risk scores.

Symptoms

Kawasaki disease presents with a characteristic “four‑plus‑one” pattern—four principal clinical findings plus one laboratory/echocardiographic feature. In IVIG‑resistant cases, the fever persists despite treatment, but the symptom profile is otherwise the same.

Principal clinical features

• Persistent fever: ≥5 days, often >39 °C (102 °F).
• Bilateral non‑exudative conjunctival injection: bright red eyes without discharge.
• Oral mucosal changes: “strawberry tongue,” cracked lips, diffuse erythema of the oropharynx.
• Extremity changes: erythema and edema of hands/feet in the acute phase, followed by desquamation (peeling) around the nails in weeks 2–3.
• Polymorphous rash: typically maculopapular, but can be scarlatiniform, urticarial, or erythema multiforme‑like.

Additional findings that raise suspicion for IVIG resistance

• Markedly elevated C‑reactive protein (CRP > 10 mg/dL) or erythrocyte sedimentation rate (ESR > 40 mm/h).
• Neutrophilia (>80 % segmented neutrophils), low hemoglobin, and hypo‑albuminemia (<3.0 g/dL).
• Elevated liver enzymes (ALT/AST), hyponatremia, or high levels of brain‑type natriuretic peptide (BNP).
• Presence of coronary artery dilation or aneurysm on the initial echocardiogram.

Causes and Risk Factors

The exact trigger for KD remains unknown, but current evidence points to an abnormal immune response to an infectious agent in genetically predisposed children.

• Genetic predisposition: Polymorphisms in ITPKC, FCGR2A, and BLK genes are associated with both KD susceptibility and IVIG resistance.
• Age: Infants <1 year old have the highest resistance rates (up to 30 %).
• Sex: Males are affected ≈1.5‑2 times more often than females; resistance appears slightly more common in males.
• Ethnicity: Children of Asian descent, especially Japanese and Korean, have higher incidence and may exhibit higher resistance.
• Immune‑related laboratory profile: High CRP, neutrophilia, low albumin, and high sodium‑binding protein (like NT‑proBNP) predict resistance (Kobayashi, Egami, and Sano scores).
• Delayed treatment: Initiating IVIG >10 days after fever onset increases the chance of resistance.

Diagnosis

Diagnosis of KD with IVIG resistance relies on recognizing the classic clinical picture, confirming persistent fever after initial IVIG, and using adjunctive laboratory and imaging tools.

Clinical criteria

1. Fever ≥5 days (or < 5 days if ≥4 principal features are present).
2. At least four of the five principal features listed above.
3. Exclusion of alternative diagnoses (e.g., scarlet fever, viral exanthems, toxic‑shock syndrome).

Definition of IVIG resistance

Recrudescent or persistent fever ≥36 hours after completion of the first IVIG infusion, without another identifiable cause.

Laboratory tests

• Complete blood count (CBC) – neutrophilia, anemia.
• Inflammatory markers – CRP, ESR.
• Serum albumin, electrolytes, liver function tests.
• Urine analysis – sterile pyuria.
• Cardiac biomarkers – BNP/NT‑proBNP (elevated in severe inflammation).

Echocardiography

All children with suspected KD should undergo a baseline transthoracic echocardiogram within 10 days of fever onset. Repeat studies are performed at 2 weeks, 6 weeks, and thereafter if abnormalities persist.

Risk‑scoring systems for predicting IVIG resistance

• Kobayashi score (Japan): Uses sodium, age, AST, neutrophils, CRP, and days of fever.
• Egami score: Relies on age, CRP, platelet count, and ALT.
• Sano score: Adds total bilirubin to the Kobayashi variables.

These scores help identify children who may benefit from intensified initial therapy.

Treatment Options

For patients who are IVIG‑resistant, the therapeutic goal is to suppress ongoing inflammation rapidly to protect the coronary arteries.

First‑line rescue therapies

• Repeat IVIG: A second 2 g/kg infusion administered 24–48 h after the first failed dose. Effective in ~50–70 % of resistant cases.
• Corticosteroids: Intravenous methylprednisolone 30 mg/kg/day for 1–3 days followed by an oral taper. Early adjunctive steroids (given with the first IVIG) have been shown to reduce resistance in high‑risk patients (RAISE study, NEJM 2017).

Second‑line (non‑IVIG) agents

• Infliximab (anti‑TNFα): 5 mg/kg single infusion; FDA‑approved for KD refractory to IVIG.
• Cyclosporine: 5 mg/kg/day divided BID; useful in patients with genetic polymorphisms affecting the NF‑κB pathway.
• Anakinra (IL‑1 receptor antagonist): 2–10 mg/kg/day subcutaneously; emerging data suggest benefit in severe, refractory KD.
• Plasma exchange: Considered in life‑threatening coronary involvement when pharmacologic options fail.

Adjunctive antiplatelet therapy

• Aspirin: High‑dose (80–100 mg/kg/day) during the acute phase, then low‑dose (3–5 mg/kg/day) once afebrile for antiplatelet effect.
• Clopidogrel or warfarin: Reserved for giant coronary aneurysms (>8 mm) or thrombosis risk.

Lifestyle and supportive care

• Hydration, rest, and fever control with acetaminophen.
• Monitoring of growth and development, especially in infants.

Living with Kawasaki disease IVIG resistance

Even after successful rescue therapy, many families wonder how to manage day‑to‑day life.

Follow‑up schedule

• Cardiology visits at 2 weeks, 6 weeks, 3 months, and then every 6–12 months based on coronary status.
• Echocardiograms according to the AHA/KD guidelines; more frequent if aneurysms are present.

Medication adherence

• Maintain low‑dose aspirin for at least 6–8 weeks; longer if coronary changes persist.
• If steroids or biologics were used, follow the taper schedule precisely to avoid rebound inflammation.

School and activity considerations

• Children with normal coronary arteries can return to regular activities after the fever resolves and aspirin is tapered.
• Those with moderate or large aneurysms may need activity restrictions (e.g., no competitive sports) and a cardiology clearance.

Psychosocial support

• Connect with KD support groups (e.g., Kawasaki Disease Foundation).
• Address parental anxiety with counseling; many families experience “post‑ICU” stress after severe disease.

Vaccination guidance

• Live vaccines (e.g., MMR, varicella) can be given after the patient is off high‑dose steroids and at least 4 weeks after the last IVIG dose.
• Inactivated vaccines are safe; however, IVIG may blunt the immune response, so schedule them before IVIG when possible.

Prevention

Because the precise trigger is unknown, primary prevention is limited. However, certain measures may reduce the likelihood of severe or resistant disease:

• Early recognition of fever lasting >5 days with the “four‑plus‑one” signs and prompt medical evaluation.
• Use of validated risk‑scoring tools (Kobayashi, Egami) to identify high‑risk patients who may benefit from adjunctive steroids at the time of first IVIG.
• Avoidance of unnecessary antibiotic or anti‑viral therapy that could mask KD symptoms.
• Education of primary‑care providers, emergency clinicians, and parents about the atypical presentation in infants (often only fever and irritability).

Complications

If IVIG resistance is not promptly addressed, inflammation can continue to damage coronary arteries.

• Coronary artery aneurysms (CAA): Occur in up to 25 % of resistant cases vs. ~5 % in IVIG‑responsive patients.
• Myocardial infarction or ischemia: Rare but can happen in giant aneurysms.
• Thrombosis: Intra‑aneurysmal clot formation leading to sudden cardiac events.
• Valvular dysfunction: Aortic or mitral valve regurgitation due to inflammatory damage.
• Peripheral artery stenosis: Long‑term sequelae leading to hypertension or limb ischemia.
• Growth retardation: Prolonged high‑dose aspirin or steroids may affect growth if not monitored.

When to Seek Emergency Care

---

Sources: American Heart Association (AHA) Kawasaki Disease Guidelines 2022; Mayo Clinic. Kawasaki Disease. Link. CDC. Kawasaki Disease Fact Sheet. Link. RAISE Study, NEJM 2017; Kobayashi et al., J Pediatr 2010; NIH National Heart, Lung, and Blood Institute.

```